Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

The adjuvant G3 promotes a Th1 polarizing innate immune response in equine PBMC.

Hellman S, Hjertner B, Morein B, Fossum C.

Vet Res. 2018 Oct 22;49(1):108. doi: 10.1186/s13567-018-0602-2.

2.

A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine.

Hjertner B, Bengtsson T, Morein B, Paulie S, Fossum C.

Vaccine. 2018 May 31;36(23):3340-3344. doi: 10.1016/j.vaccine.2018.04.054. Epub 2018 Apr 26.

3.

Evaluation of the humoral immune response to a multicomponent recombinant vaccine against S. aureus in healthy pregnant heifers.

Pujato N, Camussone CM, Renna MS, Perrig MS, Morein B, Calvinho LF, Marcipar IS.

Vet J. 2018 May;235:47-53. doi: 10.1016/j.tvjl.2018.03.005. Epub 2018 Mar 20.

PMID:
29704938
4.

A Neospora caninum vaccine using recombinant proteins fails to prevent foetal infection in pregnant cattle after experimental intravenous challenge.

Hecker YP, Cóceres V, Wilkowsky SE, Jaramillo Ortiz JM, Morrell EL, Verna AE, Ganuza A, Cano DB, Lischinsky L, Angel SO, Zamorano P, Odeón AC, Leunda MR, Campero CM, Morein B, Moore DP.

Vet Immunol Immunopathol. 2014 Dec 15;162(3-4):142-53. doi: 10.1016/j.vetimm.2014.11.001. Epub 2014 Nov 8.

PMID:
25467890
5.

Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.

Camussone CM, Pujato N, Renna MS, Veaute CM, Morein B, Marcipar IS, Calvinho LF.

Vet Immunol Immunopathol. 2014 Dec 15;162(3-4):96-107. doi: 10.1016/j.vetimm.2014.10.004. Epub 2014 Oct 14.

PMID:
25454469
6.

Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, Osterhaus AD, Morein B, Rimmelzwaan GF.

Vaccine. 2014 Sep 29;32(43):5614-23. doi: 10.1016/j.vaccine.2014.08.003. Epub 2014 Aug 17.

PMID:
25140929
7.

Immune response of heifers against a Staphylococcus aureus CP5 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant.

Camussone CM, Veaute CM, Pujato N, Morein B, Marcipar IS, Calvinho LF.

Res Vet Sci. 2014 Feb;96(1):86-94. doi: 10.1016/j.rvsc.2013.10.004. Epub 2013 Oct 23.

PMID:
24210331
8.

The nanoparticulate Quillaja saponin KGI exerts anti-proliferative effects by down-regulation of cell cycle molecules in U937 and HL-60 human leukemia cells.

Berenjian S, Hu K, Abedi-Valugerdi M, Hassan M, Bashir Hassan S, Morein B.

Leuk Lymphoma. 2014 Jul;55(7):1618-24. doi: 10.3109/10428194.2013.853301. Epub 2013 Dec 2.

PMID:
24138332
9.

The Nanoparticulate Quillaja Saponin BBE is selectively active towards renal cell carcinoma.

Hassan SB, Gullbo J, Hu K, Berenjian S, Morein B, Nygren P.

Anticancer Res. 2013 Jan;33(1):143-51.

PMID:
23267139
10.

Immune response of heifers against a Staphylococcus aureus CP5 whole cell vaccine formulated with ISCOMATRIX™ adjuvant.

Camussone CM, Veaute CM, Porporatto C, Morein B, Marcipar IS, Calvinho LF.

J Dairy Res. 2013 Feb;80(1):72-80. doi: 10.1017/S0022029912000593. Epub 2012 Nov 21.

PMID:
23171590
11.

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation.

Lövgren Bengtsson K, Morein B, Osterhaus AD.

Expert Rev Vaccines. 2011 Apr;10(4):401-3. doi: 10.1586/erv.11.25. Review. No abstract available.

PMID:
21506635
12.

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index.

Hu K, Berenjian S, Larsson R, Gullbo J, Nygren P, Lövgren T, Morein B.

Int J Nanomedicine. 2010 Feb 2;5:51-62.

13.

An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model.

Azevedo MS, Gonzalez AM, Yuan L, Jeong KI, Iosef C, Van Nguyen T, Lovgren-Bengtsson K, Morein B, Saif LJ.

Clin Vaccine Immunol. 2010 Mar;17(3):420-8. doi: 10.1128/CVI.00395-09. Epub 2010 Jan 27.

14.

Immune responsiveness in the neonatal period.

Morein B, Blomqvist G, Hu K.

J Comp Pathol. 2007 Jul;137 Suppl 1:S27-31. Epub 2007 Jun 4. Review.

PMID:
17548093
15.

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.

Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B, Lehner T, Heeney JL.

J Med Virol. 2007 May;79(5):474-82.

PMID:
17385685
16.

High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen.

Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ.

Clin Vaccine Immunol. 2006 Apr;13(4):475-85.

17.

Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine.

Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ.

Vaccine. 2006 Mar 20;24(13):2302-16. Epub 2005 Dec 1.

PMID:
16361002
18.

The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703.

Hu KF, Regner M, Siegrist CA, Lambert P, Chen M, Bengtsson KL, Morein B.

FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):269-76.

19.

Bovine respiratory syncytial virus ISCOMs--protection in the presence of maternal antibodies.

Hägglund S, Hu KF, Larsen LE, Hakhverdyan M, Valarcher JF, Taylor G, Morein B, Belák S, Alenius S.

Vaccine. 2004 Dec 16;23(5):646-55.

PMID:
15542185
20.

Current status and potential application of ISCOMs in veterinary medicine.

Morein B, Hu KF, Abusugra I.

Adv Drug Deliv Rev. 2004 Jun 23;56(10):1367-82. Review.

PMID:
15191787
21.

Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection.

Regner M, Culley F, Fontannaz P, Hu K, Morein B, Lambert PH, Openshaw P, Siegrist CA.

Microbes Infect. 2004 Jun;6(7):666-75.

PMID:
15158774
22.

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers WM, Ten Haaft PJ, Niphuis H, Koornstra W, Bieler K, Köstler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL.

J Virol. 2004 Apr;78(7):3333-42.

23.

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

González AM, Nguyen TV, Azevedo MS, Jeong K, Agarib F, Iosef C, Chang K, Lovgren-Bengtsson K, Morein B, Saif LJ.

Clin Exp Immunol. 2004 Mar;135(3):361-72.

24.

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G.

Vaccine. 2004 Jan 26;22(5-6):747-54.

PMID:
14741168
25.

Experimental field trial with an immunostimulating complex (ISCOM) vaccine against contagious bovine pleuropneumonia.

Hübschle OJ, Tjipura-Zaire G, Abusugra I, di Francesca G, Mettler F, Pini A, Morein B.

J Vet Med B Infect Dis Vet Public Health. 2003 Aug;50(6):298-303.

PMID:
14629002
26.

Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs.

Nguyen TV, Iosef C, Jeong K, Kim Y, Chang KO, Lovgren-Bengtsson K, Morein B, Azevedo MS, Lewis P, Nielsen P, Yuan L, Saif LJ.

Vaccine. 2003 Sep 8;21(25-26):4059-70.

PMID:
12922143
27.

Influence of maternal immunity on antibody and T-cell response in mice.

Blomqvist GA, Lövgren-Bengtsson K, Morein B.

Vaccine. 2003 May 16;21(17-18):2022-31.

PMID:
12706692
28.

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus.

Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljeström P.

J Immunol. 2002 Sep 15;169(6):3208-16.

29.

Transmission pattern of parainfluenza 3 virus in guinea pig breeding herds.

Blomqvist GA, Martin K, Morein B.

Contemp Top Lab Anim Sci. 2002 Jul;41(4):53-7.

PMID:
12109899
30.

Immunity in neonates.

Morein B, Abusugra I, Blomqvist G.

Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):207-13. Review.

PMID:
12072236
31.

Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes.

Iosef C, Van Nguyen T, Jeong Ki, Bengtsson K, Morein B, Kim Y, Chang KO, Azevedo MS, Yuan L, Nielsen P, Saif LJ.

Vaccine. 2002 Mar 15;20(13-14):1741-53.

PMID:
11906761
32.
33.

Immunostimulating complexes (ISCOMs) for nasal vaccination.

Hu KF, Lövgren-Bengtsson K, Morein B.

Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):149-59. Review.

PMID:
11516786
34.

Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.

Verschoor EJ, Davis D, van Gils M, Koopman G, Mooij P, Oostermeijer H, Haaft PT, Verstrepen B, Rosenwirth B, Morein B, Barnett SW, Heeney JL.

J Med Primatol. 1999 Aug-Oct;28(4-5):224-32.

PMID:
10593489
35.

Immunomodulation by iscoms, immune stimulating complexes.

Morein B, Bengtsson KL.

Methods. 1999 Sep;19(1):94-102. Review.

PMID:
10525444
36.

Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs.

van Pinxteren LA, Bruce MG, Campbell I, Wood A, Clarke CJ, Bellman A, Morein B, Snodgrass DR.

Vet Immunol Immunopathol. 1999 Oct 1;71(1):53-67.

PMID:
10522786
37.

Quillaja saponin formulations that stimulate proinflammatory cytokines elicit a potent acquired cell-mediated immunity.

Behboudi S, Morein B, Villacres-Eriksson MC.

Scand J Immunol. 1999 Oct;50(4):371-7.

38.

Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions.

Ekström J, Hu KF, Bengtsson KL, Morein B.

Vaccine. 1999 Jun 4;17(20-21):2690-701.

PMID:
10418920
39.

Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes.

Hu KF, Ekström J, Merza M, Lövgren-Bengtsson K, Morein B.

Med Microbiol Immunol. 1999 May;187(4):191-8.

PMID:
10363675
40.

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

Heeney J, Akerblom L, Barnett S, Bogers W, Davis D, Fuller D, Koopman G, Lehner T, Mooij P, Morein B, de Giuli Morghen C, Rosenwirth B, Verschoor E, Wagner R, Wolf H.

Immunol Lett. 1999 Mar;66(1-3):189-95.

PMID:
10203054
41.

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.

Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ.

Vaccine. 1999 Mar 5;17(9-10):1282-90.

PMID:
10195641
42.

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL.

J Virol. 1999 Apr;73(4):3292-300.

44.

ISCOM: a delivery system for neonates and for mucosal administration.

Morein B, Villacrés-Eriksson M, Ekström J, Hu K, Behboudi S, Lövgren-Bengtsson K.

Adv Vet Med. 1999;41:405-13. Review. No abstract available.

PMID:
9890031
45.

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection.

Heeney JL, van Gils ME, van der Meide P, de Giuli Morghen C, Ghioni C, Gimelli M, Raddelli A, Davis D, Akerblom L, Morein B.

J Med Primatol. 1998 Apr-Jun;27(2-3):50-8.

PMID:
9747943
46.

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.

Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli Morghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D.

Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10803-8.

48.
49.

Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction.

Villacres MC, Behboudi S, Nikkila T, Lovgren-Bengtsson K, Morein B.

Cell Immunol. 1998 Apr 10;185(1):30-8.

PMID:
9636680
50.

An immunoaffinity-purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-beta-mediated mechanism.

Hansen DS, Villacres-Eriksson M, Akerblom L, Hellman U, Segura E, Carlomagno M, Morein B.

Scand J Immunol. 1998 May;47(5):509-16.

Supplemental Content

Loading ...
Support Center